S1p receptor agonist 1 (oral administration; 0.01 mg/kg-1 mg/kg) at all dose is active, and only a dose of 0.01 mg/kg is required to observe a decrease in the number of peripheral blood lymphocytes by more than 50% and a decrease in the 1 mg/kg dose. Besides, this compound is lymphocyte-specific, which dose not significantly alter the number of peripheral monocytes and other white blood cells in SD rats.
S1p receptor agonist 1 (oral administration; 3 mg/kg; 12 days) is has been proved to block lymphocyte efflux. In the development of type II collagen-induced arthritis in rat model, compound 2 is effective in inhibiting the development of joint swelling in arthritis and joint structure destruction.
S1p receptor agonist 1 (oral administration; 0.3-1mg/kg; 30 days; once daily) inhibits the development of experimental autoimmune encephalitis (EAE) as a dose-dependent manner in mice model.
Animal Model: |
Lewis rats |
Dosage: |
3 mg/kg |
Administration: |
Oral administration |
Result: |
Decreased the severity score of arthritis in the four-legged rats. |
Animal Model: |
Female C57BL/6 mice |
Dosage: |
0.03, 0.1, and 1 mg/kg |
Administration: |
Oral administration |
Result: |
Decreased the severity score of EAE in MOG 35-55 induced mice. |